Cargando…

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV

After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Bunse, Lukas, Sommerer, Claudia, Tan, Chin Leng, Korell, Felix, Schmitt, Anita, Hückelhoven-Krauss, Angela, Neuber, Brigitte, Mertens, Thomas, Platten, Michael, Green, Edward W., Zeier, Martin, Schmitt, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835207/
https://www.ncbi.nlm.nih.gov/pubmed/35162953
http://dx.doi.org/10.3390/ijms23031029
_version_ 1784649372652273664
author Bunse, Lukas
Sommerer, Claudia
Tan, Chin Leng
Korell, Felix
Schmitt, Anita
Hückelhoven-Krauss, Angela
Neuber, Brigitte
Mertens, Thomas
Platten, Michael
Green, Edward W.
Zeier, Martin
Schmitt, Michael
author_facet Bunse, Lukas
Sommerer, Claudia
Tan, Chin Leng
Korell, Felix
Schmitt, Anita
Hückelhoven-Krauss, Angela
Neuber, Brigitte
Mertens, Thomas
Platten, Michael
Green, Edward W.
Zeier, Martin
Schmitt, Michael
author_sort Bunse, Lukas
collection PubMed
description After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal disease listed for kidney transplantation were subjected to CMV phosphoprotein 65 (CMVpp65) peptide vaccination and further investigated for T-cell responses. To this end, CMV-specific CD8(+) T cells were characterized by bulk T-cell-receptor (TCR) repertoire sequencing and combined single-cell RNA and TCR sequencing. In patients mounting an immune response to the vaccine, a common SYE(N)E TCR motif known to bind CMVpp65 was detected. CMV-peptide-vaccination-responder patients had TCR features distinct from those of non-responders. In a non-responder patient, a monoclonal inflammatory T-cell response was detected upon CMV reactivation. The identification of vaccine-induced CMV-reactive TCRs motifs might facilitate the development of cellular therapies for patients wait-listed for kidney transplantation.
format Online
Article
Text
id pubmed-8835207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88352072022-02-12 Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV Bunse, Lukas Sommerer, Claudia Tan, Chin Leng Korell, Felix Schmitt, Anita Hückelhoven-Krauss, Angela Neuber, Brigitte Mertens, Thomas Platten, Michael Green, Edward W. Zeier, Martin Schmitt, Michael Int J Mol Sci Article After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal disease listed for kidney transplantation were subjected to CMV phosphoprotein 65 (CMVpp65) peptide vaccination and further investigated for T-cell responses. To this end, CMV-specific CD8(+) T cells were characterized by bulk T-cell-receptor (TCR) repertoire sequencing and combined single-cell RNA and TCR sequencing. In patients mounting an immune response to the vaccine, a common SYE(N)E TCR motif known to bind CMVpp65 was detected. CMV-peptide-vaccination-responder patients had TCR features distinct from those of non-responders. In a non-responder patient, a monoclonal inflammatory T-cell response was detected upon CMV reactivation. The identification of vaccine-induced CMV-reactive TCRs motifs might facilitate the development of cellular therapies for patients wait-listed for kidney transplantation. MDPI 2022-01-18 /pmc/articles/PMC8835207/ /pubmed/35162953 http://dx.doi.org/10.3390/ijms23031029 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bunse, Lukas
Sommerer, Claudia
Tan, Chin Leng
Korell, Felix
Schmitt, Anita
Hückelhoven-Krauss, Angela
Neuber, Brigitte
Mertens, Thomas
Platten, Michael
Green, Edward W.
Zeier, Martin
Schmitt, Michael
Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
title Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
title_full Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
title_fullStr Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
title_full_unstemmed Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
title_short Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
title_sort common t-cell-receptor motifs and features in patients with cytomegalovirus (cmv)-seronegative end-stage renal disease receiving a peptide vaccination against cmv
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835207/
https://www.ncbi.nlm.nih.gov/pubmed/35162953
http://dx.doi.org/10.3390/ijms23031029
work_keys_str_mv AT bunselukas commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT sommererclaudia commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT tanchinleng commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT korellfelix commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT schmittanita commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT huckelhovenkraussangela commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT neuberbrigitte commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT mertensthomas commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT plattenmichael commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT greenedwardw commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT zeiermartin commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv
AT schmittmichael commontcellreceptormotifsandfeaturesinpatientswithcytomegaloviruscmvseronegativeendstagerenaldiseasereceivingapeptidevaccinationagainstcmv